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Gleason score of tumors found with transrectal ultrasound compared
to radical prostatectomy (ranging from 30 to 50%, depending on initial
Gleason score) (Pinthus et al., 2006; Corcoran et al., 2011). This high-
resolution technique may further improve lesion characterization and
ultimately be used to perform MRI diffusion-weighted imaging-
targeted biopsy.Multiparametric MRI of the prostate has become a valuable imaging
tool to detect clinically signiﬁcant prostate cancer (Panebianco et al.,
2015; Schoots et al., 2015). This tool consists of anatomical and func-
tional imaging techniques. Currently, diffusion-weighted imaging is
the most promising functional technique to detect and characterize
prostate cancer. Despite its huge potential, it has some limitations that
may hamper further implementation in the clinical practice. The
signal-to-noise ratio is currently the major limitation. As a result, the
highest in plane resolution, achievable with commercially available se-
quences, is in the range of 1.5 mm (Barentsz et al., 2012).
In EBioMedicine, Sharif-Afshar et al. present an important step for-
ward to overcome the current limitations of diffusion-weighted imag-
ing (Sharif-Afshar et al., 2016). This prospective pilot study included
17 men scheduled for prostate biopsy for active surveillance. They
underwentmultiparametricMRI of the prostate prior to the prostate bi-
opsy. Additionally, the men underwent a high resolution three-
dimensional multi-shot diffusion-weighted imaging sequence, which
has advantages over two-dimensional single-shot echo-planer imaging.
These include markedly reduced geometric distortion, minimization of
susceptibility-related artifacts, and higher achievable spatial resolution.
This multishot technique allows differentiation of signal and noise, fur-
ther improving resolution. The reported in plane resolution is
0.9 × 0.9× 3.5mm3,which is improved by a factor 4.4 to 5.4. This result-
ed in a signiﬁcantly higher area under the ROC for the high resolution
diffusion-weighted MRI compared to the standard clinical diffusion-
weighted imaging. Subsequently, the new technique identiﬁed signiﬁ-
cantly more biopsy-proven lesions than standard diffusion MRI.
The investigated functional imaging technique has great potentials.
Diffusion-weightedMRI may provide an aid to establish the aggressive-
ness of prostate cancer and help predict those tumors most likely toom.2016.03.041.
. This is an open access article underprogress rapidly. Prostate biopsies frequently underestimate the ‘true’
A question that arises is whether this higher spatial resolution will
improve patient selection for active surveillance. Particular in this pa-
tient group, it is difﬁcult to ﬁnd low-grade lesions with diffusion-
weighted imaging. Contrast-enhanced MRI is more helpful in ﬁnding
those lesions. On the other hand, the proposed technique may be used
to exclude males from the active surveillance program.
To conclude, high-resolution diffusion-weighted imaging of the
prostate has the potential to further improve lesion characterization
and visibility. It has paved the way for more accurate MRI-targeted
biopsy.
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